The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis.
about
Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adultsXpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adultsScreening strategies for active tuberculosis: focus on cost-effectivenessScreening for Tuberculosis Among Adults Newly Diagnosed With HIV in Sub-Saharan Africa: A Cost-Effectiveness AnalysisHow can mathematical models advance tuberculosis control in high HIV prevalence settings?HIV, tuberculosis, and noncommunicable diseases: what is known about the costs, effects, and cost-effectiveness of integrated care?Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluationDiagnostic point-of-care tests in resource-limited settingsModeling the cost-effectiveness of HIV treatment: how to buy the most 'health' when resources are limited.Modeling of novel diagnostic strategies for active tuberculosis - a systematic review: current practices and recommendations.Immunogenicity of a fusion protein containing immunodominant epitopes of Ag85C, MPT51, and HspX from Mycobacterium tuberculosis in mice and active TB infection.Cost-effectiveness analysis of community active case finding and household contact investigation for tuberculosis case detection in urban Africa.Automated chest-radiography as a triage for Xpert testing in resource-constrained settings: a prospective study of diagnostic accuracy and costsComparative Yield of Different Diagnostic Tests for Tuberculosis among People Living with HIV in Western Kenya.Transforming TB diagnosis: can patients and control programs afford to wait?Economic challenges associated with tuberculosis diagnostic development.Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care testChallenges in evaluating the cost-effectiveness of new diagnostic tests for HIV-associated tuberculosis.Using Xpert MTB/RIFReducing deaths from tuberculosis in antiretroviral treatment programmes in sub-Saharan Africa.Incorporating Demand and Supply Constraints into Economic Evaluations in Low-Income and Middle-Income CountriesPerformance of symptom-based tuberculosis screening among people living with HIV: not as great as hopedHigh tuberculosis prevalence in a South African prison: the need for routine tuberculosis screeningCost utility of lateral-flow urine lipoarabinomannan for tuberculosis diagnosis in HIV-infected African adults.Tuberculosis screening in high human immunodeficiency virus prevalence settings: turning promise into reality.Management of tuberculosis and latent tuberculosis infection in human immunodeficiency virus-infected persons.Evaluation of the Cepheid Xpert MTB/RIF assay.Rolling Out Xpert® MTB/RIF for TB Detection in HIV-Infected Populations:An Opportunity for Systems StrengtheningHigher cost of implementing Xpert(®) MTB/RIF in Ugandan peripheral settings: implications for cost-effectiveness.Microscopic observation drug-susceptibility assay vs. Xpert® MTB/RIF for the diagnosis of tuberculosis in a rural African setting: a cost-utility analysis.Impact and cost-effectiveness of current and future tuberculosis diagnostics: the contribution of modellingCost-effectiveness of WHO-Recommended Algorithms for TB Case Finding at Ethiopian HIV Clinics.The investment case for hepatitis B and C in South Africa: adaptation and innovation in policy analysis for disease program scale-up.Disparities in model-based cost-effectiveness analyses of tuberculosis diagnosis: A systematic review.Rapid urine-based screening for tuberculosis in HIV-positive patients admitted to hospital in Africa (STAMP): a pragmatic, multicentre, parallel-group, double-blind, randomised controlled trial
P2860
Q24200879-69A249D2-BD53-45AC-884A-A7CEB662FC95Q24201466-D44522F2-5C93-4A5C-AACF-AA5BC53BA421Q26740226-6A4D54A0-6F38-4017-B175-50E3E8F82D05Q26779464-6C6C11A4-744D-4155-B07B-B6E81970952AQ26824057-F62F67A6-106F-48E8-8B40-298012935DDEQ27010874-74DB57D3-0C4D-42F7-AC3E-E4DF6D714CA6Q28485280-6FB2082B-B1E7-4351-B57B-FF2232A8762EQ33590492-80BED188-2726-4154-B5A2-EF3981486BF1Q33854542-6D3DA197-6044-457D-976F-1CD39B9DE7EBQ34395434-FC7FED33-9C38-4CA7-877E-1045899D36DCQ34469190-C8924344-4FC5-4E0B-8F46-BDF63D331092Q35057710-FBD3B6F2-A6CF-4C46-BDB7-247A4C3AF409Q35891122-0F46E664-A2C3-4B58-B720-EF9DEDB88BBCQ35972660-4767F9D9-CE23-4EA0-AAD5-9CD9FA2BC7F5Q36149571-D586E3E8-EE4C-46B8-ABBC-837B7C28D9A1Q36160928-562AD290-5072-4B79-AF25-420315908D66Q36833723-E83E9C52-C77C-4521-8C3A-439137FCF0E4Q37151512-3415E0C6-17E5-40E7-82B6-EF12AFF3159BQ37202392-FE9A9860-2BC5-41E5-B607-2E8A7CB9BBB8Q37285167-7BA3E58F-E4F7-447B-AD8C-7E898442F08FQ37295972-87629A1A-3579-4025-B56A-149C9BD220F1Q37424113-7647DCAC-1313-4E7A-9C01-FE52BE0CA258Q37534641-BE4E1D41-0FEE-4819-BAFF-DDE1CC0F6563Q37569237-C7F25FA4-D2C8-4F5E-8C11-3D29557FB067Q37664997-524C1DC7-E3E1-4505-9028-101978C234E2Q38107500-1674118D-EEA5-43B7-B319-782CB838FD9DQ38265418-5FD9218A-7D46-4FEB-AC82-FBB73BB3A767Q38645708-440AB4FE-61A7-4FCD-AAB0-1F819FB83590Q38853460-A5B16CBE-1391-4CAC-845A-6260F94E0662Q39592738-1682B678-9E25-4B81-AE2C-1BE3BEED3FC2Q42546968-6A22BDEA-5D1F-4E10-8D54-A1EC42D5D76BQ49332222-97194B4F-EDC6-4939-9AF2-DA1FA3D3F9E8Q52660642-6FE7796B-99E6-4577-A6FE-1315CF9B99ACQ55016083-16C9B62A-DDAE-4826-A643-5BBE35B2047BQ56931078-CF1F2939-BD12-4062-9609-0D730D85312E
P2860
The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
The cost-effectiveness of rout ...... rapy: a model-based analysis.
@ast
The cost-effectiveness of rout ...... rapy: a model-based analysis.
@en
type
label
The cost-effectiveness of rout ...... rapy: a model-based analysis.
@ast
The cost-effectiveness of rout ...... rapy: a model-based analysis.
@en
prefLabel
The cost-effectiveness of rout ...... rapy: a model-based analysis.
@ast
The cost-effectiveness of rout ...... rapy: a model-based analysis.
@en
P2093
P2860
P50
P1433
P1476
The cost-effectiveness of rout ...... rapy: a model-based analysis.
@en
P2093
C Robert Horsburgh
Corina Rusu
Farzad Noubary
Melissa A Bender
P2860
P304
P356
10.1097/QAD.0B013E3283522D47
P407
P577
2012-05-01T00:00:00Z